摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(2β,3α,5α)-3-hydroxy-2-(4-{[(2S)-1-(quinolin-2-ylcarbonyl)pyrrolidin-2-yl]carbonyl}piperazin-1-yl)androstan-17-one | 1228036-75-6

中文名称
——
中文别名
——
英文名称
(2β,3α,5α)-3-hydroxy-2-(4-{[(2S)-1-(quinolin-2-ylcarbonyl)pyrrolidin-2-yl]carbonyl}piperazin-1-yl)androstan-17-one
英文别名
(2S,3S,5S,8R,9S,10S,13S,14S)-3-hydroxy-10,13-dimethyl-2-[4-[(2S)-1-(quinoline-2-carbonyl)pyrrolidine-2-carbonyl]piperazin-1-yl]-1,2,3,4,5,6,7,8,9,11,12,14,15,16-tetradecahydrocyclopenta[a]phenanthren-17-one
(2β,3α,5α)-3-hydroxy-2-(4-{[(2S)-1-(quinolin-2-ylcarbonyl)pyrrolidin-2-yl]carbonyl}piperazin-1-yl)androstan-17-one化学式
CAS
1228036-75-6
化学式
C38H50N4O4
mdl
——
分子量
626.839
InChiKey
XPCQPZXYBZFMOG-OBLTXFSLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    5.2
  • 重原子数:
    46
  • 可旋转键数:
    3
  • 环数:
    8.0
  • sp3杂化的碳原子比例:
    0.68
  • 拓扑面积:
    94
  • 氢给体数:
    1
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量
  • 下游产品
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    (2β,3α,5α)-3-hydroxy-2-(4-{[(2S)-1-(quinolin-2-ylcarbonyl)pyrrolidin-2-yl]carbonyl}piperazin-1-yl)androstan-17-one 在 copper(I) bromide 作用下, 以 甲醇 为溶剂, 反应 15.0h, 以44%的产率得到
    参考文献:
    名称:
    一种氨基甾体化合物及其制备方法和应用
    摘要:
    本申请提供了一种氨基甾体化合物及其制备方法和应用,所述氨基甾体化合物包括如式I或式II所示的化学式中的至少一种, 其中,R1、R2、R3、R4、R5独立地选自H、含卤素基团、C1~C10的烷基、C2~C10的烯基、C2~C10的炔基、C3~C10的环烷基、C6~C10芳基或C5~C10杂芳基;并且R1、R2中至少一个为含卤素基团;R3、R4、R5中至少一个为含卤素基团。
    公开号:
    CN114702544A
  • 作为产物:
    描述:
    2α,3α-epoxy-5α-androstan-17-one 在 benzotriazol-1-yloxyl-tris-(pyrrolidino)-phosphonium hexafluorophosphate 、 1-羟基苯并三唑N,N-二异丙基乙胺 作用下, 以 N,N-二甲基甲酰胺 为溶剂, 反应 48.0h, 生成 (2β,3α,5α)-3-hydroxy-2-(4-{[(2S)-1-(quinolin-2-ylcarbonyl)pyrrolidin-2-yl]carbonyl}piperazin-1-yl)androstan-17-one
    参考文献:
    名称:
    Chemical synthesis, NMR analysis and evaluation on a cancer xenograft model (HL-60) of the aminosteroid derivative RM-133
    摘要:
    The aminosteroid derivative RM-133 has been reported to be a promising pro-apoptotic agent showing activity on various cancer cell lines. Following the development of solid-phase synthesis that generated a series of libraries of aminosteroid derivatives, we now report the development of a convenient liquid phase chemical synthesis of RM-133, the most promising candidate, in order to obtain sufficient quantities to proceed with the first preclinical assays. A simple and convergent six-step synthesis was designed and allowed the preparation of a gram-quantity scale of RM-133. This aminosteroid derivative was also fully characterized by NMR experiments which revealed an interesting mixture of conformers. Finally, the in vivo potency of RM-133 was evaluated on a xenograft model in nude mice with HL-60 tumors, which has resulted in the blocking of tumor progression by 57%. (C) 2014 Elsevier Inc. All rights reserved.
    DOI:
    10.1016/j.steroids.2014.01.008
点击查看最新优质反应信息

文献信息

  • Chemical synthesis, cytotoxicity, selectivity and bioavailability of 5α-androstane-3α,17β-diol derivatives
    作者:Diana Ayan、René Maltais、Audrey Hospital、Donald Poirier
    DOI:10.1016/j.bmc.2014.09.026
    日期:2014.11
    Aminosteroid derivatives represent a new family of compounds with promising antiproliferative activity over different cancer cell lines. Among all the aminosteroid derivatives synthesised in our laboratory, we have identified E-37P as one of the more potent when tested in vitro. Unfortunately, the pharmacokinetic properties of E-37P decrease its effectiveness when tested in vivo. To improve the bioavailability and increase the efficiency of aminosteroid E-37P, two series of analog compounds were synthesised by classic chemical synthesis, they were then characterized, and the concentration that inhibits 50% of cell proliferation (IC50) was determined on different cell lines. RM-133, a 5 alpha-androstane-3 alpha, 17 beta-diol derivative with a quinoline nucleus at the end of the piperazine-proline side-chain at position 2 beta and an ethinyl at position 17 alpha, showed very good antiproliferative activity among the five cancer cell lines studied (IC50 = 0.1, 0.1, 0.1, 2.0 and 1.1 mu M for HL-60, MCF-7, T-47D, LNCaP and WEHI-3, respectively). Moreover, the plasmatic concentration of RM-133 at 3 h, when injected subcutaneously in rats, was 2.3-fold higher than that of E-37P (151 vs 64.8 ng/mL). Furthermore, RM-133 weakly inhibited the two representative liver enzymes, CYP3A4 and CYP2D6, indicating a very low risk of drug-drug interactions. The cytotoxicity of RM-133 against normal cells was tested on peripheral blood lymphocytes (PBL) obtained from different donors and previously activated with phytohemagglutinin-L. PBL responded differently to treatment with RM-133, we observed a stimulation of cell proliferation and/or cytotoxicity in a dose-dependent manner. Based on these results, additional studies are currently underway to evaluate the selectivity of our lead compound against normal cell lines in a more detailed fashion. (C) 2014 Elsevier Ltd. All rights reserved.
  • Chemical synthesis, NMR analysis and evaluation on a cancer xenograft model (HL-60) of the aminosteroid derivative RM-133
    作者:René Maltais、Audrey Hospital、Audrey Delhomme、Jenny Roy、Donald Poirier
    DOI:10.1016/j.steroids.2014.01.008
    日期:2014.4
    The aminosteroid derivative RM-133 has been reported to be a promising pro-apoptotic agent showing activity on various cancer cell lines. Following the development of solid-phase synthesis that generated a series of libraries of aminosteroid derivatives, we now report the development of a convenient liquid phase chemical synthesis of RM-133, the most promising candidate, in order to obtain sufficient quantities to proceed with the first preclinical assays. A simple and convergent six-step synthesis was designed and allowed the preparation of a gram-quantity scale of RM-133. This aminosteroid derivative was also fully characterized by NMR experiments which revealed an interesting mixture of conformers. Finally, the in vivo potency of RM-133 was evaluated on a xenograft model in nude mice with HL-60 tumors, which has resulted in the blocking of tumor progression by 57%. (C) 2014 Elsevier Inc. All rights reserved.
  • 一种氨基甾体化合物及其制备方法和应用
    申请人:上海醇健实业发展有限公司
    公开号:CN114702544A
    公开(公告)日:2022-07-05
    本申请提供了一种氨基甾体化合物及其制备方法和应用,所述氨基甾体化合物包括如式I或式II所示的化学式中的至少一种, 其中,R1、R2、R3、R4、R5独立地选自H、含卤素基团、C1~C10的烷基、C2~C10的烯基、C2~C10的炔基、C3~C10的环烷基、C6~C10芳基或C5~C10杂芳基;并且R1、R2中至少一个为含卤素基团;R3、R4、R5中至少一个为含卤素基团。
查看更多